Current and historical daily PE Ratio for Moderna Inc (
BSP:M1RN34
) from 2020 to Apr 19 2024. The price to earnings ratio is calculated by taking the current stock price and dividing it by the most recent trailing twelve-month earnings per share (EPS) number. The data is updated every 20 minutes during market hours. The PE ratio can be viewed as the number of years it takes for the company to earn back the price you pay for the stock. Therefore, lower-P/E stocks are more attractive than higher P/E stocks so long as the PE ratio is positive. Also for stocks with the same PE ratio, the one with faster growth business is more attractive. Moderna stock (BSP:M1RN34) PE ratio as of Apr 19 2024 is 0.
More Details
Moderna Inc (BSP:M1RN34) PE Ratio (TTM) Chart
Moderna Inc (BSP:M1RN34) PE Ratio (TTM) Historical Data
View and export this data going back to 2020. Start your Free Trial
Total 915
- 1
- 2
- 3
- 4
- 5
- 6
- 11
| Moderna PE Ratio (TTM) Historical Data | |||
|---|---|---|---|
| Date | PE Ratio (TTM) Data | Date | PE Ratio (TTM) Data |
| 2024-04-19 | At Loss | 2024-02-15 | At Loss |
| 2024-04-18 | At Loss | 2024-02-14 | At Loss |
| 2024-04-17 | At Loss | 2024-02-13 | At Loss |
| 2024-04-16 | At Loss | 2024-02-12 | At Loss |
| 2024-04-15 | At Loss | 2024-02-09 | At Loss |
| 2024-04-12 | At Loss | 2024-02-08 | At Loss |
| 2024-04-11 | At Loss | 2024-02-07 | At Loss |
| 2024-04-10 | At Loss | 2024-02-06 | At Loss |
| 2024-04-09 | At Loss | 2024-02-05 | At Loss |
| 2024-04-08 | At Loss | 2024-02-02 | At Loss |
| 2024-04-05 | At Loss | 2024-02-01 | At Loss |
| 2024-04-04 | At Loss | 2024-01-31 | At Loss |
| 2024-04-03 | At Loss | 2024-01-30 | At Loss |
| 2024-04-02 | At Loss | 2024-01-29 | At Loss |
| 2024-04-01 | At Loss | 2024-01-26 | At Loss |
| 2024-03-28 | At Loss | 2024-01-25 | At Loss |
| 2024-03-27 | At Loss | 2024-01-24 | At Loss |
| 2024-03-26 | At Loss | 2024-01-23 | At Loss |
| 2024-03-25 | At Loss | 2024-01-22 | At Loss |
| 2024-03-22 | At Loss | 2024-01-19 | At Loss |
| 2024-03-21 | At Loss | 2024-01-18 | At Loss |
| 2024-03-20 | At Loss | 2024-01-17 | At Loss |
| 2024-03-19 | At Loss | 2024-01-16 | At Loss |
| 2024-03-18 | At Loss | 2024-01-15 | At Loss |
| 2024-03-15 | At Loss | 2024-01-12 | At Loss |
| 2024-03-14 | At Loss | 2024-01-11 | At Loss |
| 2024-03-13 | At Loss | 2024-01-10 | At Loss |
| 2024-03-12 | At Loss | 2024-01-09 | At Loss |
| 2024-03-11 | At Loss | 2024-01-08 | At Loss |
| 2024-03-08 | At Loss | 2024-01-05 | At Loss |
| 2024-03-07 | At Loss | 2024-01-04 | At Loss |
| 2024-03-06 | At Loss | 2024-01-03 | At Loss |
| 2024-03-05 | At Loss | 2024-01-02 | At Loss |
| 2024-03-04 | At Loss | 2024-01-01 | At Loss |
| 2024-03-01 | At Loss | 2023-12-28 | At Loss |
| 2024-02-29 | At Loss | 2023-12-27 | At Loss |
| 2024-02-28 | At Loss | 2023-12-26 | At Loss |
| 2024-02-27 | At Loss | 2023-12-22 | At Loss |
| 2024-02-26 | At Loss | 2023-12-21 | At Loss |
| 2024-02-23 | At Loss | 2023-12-20 | At Loss |
| 2024-02-22 | At Loss | 2023-12-19 | At Loss |
| 2024-02-21 | At Loss | 2023-12-18 | At Loss |
| 2024-02-20 | At Loss | 2023-12-15 | At Loss |
| 2024-02-19 | At Loss | 2023-12-14 | At Loss |
| 2024-02-16 | At Loss | 2023-12-13 | At Loss |
Moderna Inc (BSP:M1RN34) PE Ratio (TTM) Comparison
| Company | Market Cap(Mil) | PE Ratio (TTM) |
|---|
Business Description
Business Description
Moderna Inc
NAICS : 325412
SIC : 2836
ISIN : BRM1RNBDR006
Share Class Description:
BSP:M1RN34: BRDRCompare
Compare
Traded in other countries / regions
MRNA.USAM1RN34.Brazil0A45.UK0QF.Germany1MRNA.ItalyMRNA.MexicoMRNA.AustriaMRNA.PeruMRNA_KZ.Kazakhstan IPO Date
2020-10-13Description
Moderna is a commercial-stage biotech that was founded in 2010 and had its initial public offering in December 2018. The firm's mRNA technology was rapidly validated with its COVID-19 vaccine, which was authorized in the United States in December 2020. Moderna had 39 mRNA development candidates in clinical trials as of mid-2023. Programs span a wide range of therapeutic areas, including infectious disease, oncology, cardiovascular disease, and rare genetic diseases.
Survey
We'd love to learn more about your experiences on GuruFocus.com and how we can improve!
Take Survey
Follow Us
Disclaimers